Developer docs
API playgroundTry for free, no card

Search company profiles

HiFiBiO Cambridge

Full company profile

uuid0007t3n

Namestring
HiFiBiO Cambridge
Legal namestring
HiFiBiO Therapeutics, Inc.
Websiteurl
hifibio.com
Company typeenum
Private
Founded yearint
2017
Descriptiontext

HiFiBiO Therapeutics is a private, clinical-stage biotherapeutics company developing immunotherapies for cancer and immunology & inflammation (I&I) diseases. The company is built around its proprietary Drug Intelligence Science (DIS®) platform, which combines single-cell screening technology — embodied in the CelliGo™ microfluidic system capable of screening millions of species-agnostic B cells within hours — with AI/ML-driven bioinformatics (AbSolution™) for antibody binding prediction, affinity maturation, target discovery, and predictive biomarker identification. HiFiBiO has internally discovered 8 clinical candidates, cleared 6 INDs, and completed 4 Phase I dose-escalation trials; its active clinical pipeline includes the TNFR2 agonist emunkitug (HFB200301), the BTLA antagonist HFB200603, the OX40 agonist nuvustotug (HFB301001), and the BTLA agonist HFB200604 in I&I.

The company operates laboratory and operational facilities across three continents — Cambridge (US headquarters), Paris (France, original single-cell platform site), Shanghai, Hangzhou, and Hong Kong (China) — and pursues an open-innovation business model centred on out-licensing and co-development. Revenue is generated via upfront payments, development and commercial milestones, and royalties from partners rather than direct product sales; the landmark FibroGen agreement (June 2021) delivered $25M upfront plus up to $1.1B in potential milestones across three programs, followed by a $35M option exercise payment for the CCR8 program in December 2021. Novartis has entered clinical-supply agreements for combination studies with tislelizumab, and HiFiBiO participates in the REMISSION consortium under the France 2030 Initiative. No products are commercially approved, and the company is funded by a $75M Series D (2021) alongside prior venture capital from IDG Capital, Mirae Asset Capital, HongShan, and Nest.Bio Ventures.

Short descriptiontext

HiFiBiO Therapeutics is a private clinical-stage biotech using its proprietary DIS® single-cell and AI/ML platform to discover and develop immunotherapies for cancer and inflammatory diseases, monetising assets primarily through out-licensing and milestone-based partnerships with pharmaceutical companies.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersCambridge, United States
HQ citystring
Cambridge
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices6 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
immunotherapy drug discovery, single cell antibody platform, clinical stage biotherapeutics, immuno oncology pipeline, translational drug intelligence
Industry2 codes
PRIMARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Pharmaceutical Preparation Manufacturing325412
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Pharmaceutical Preparations2834
Product category
Clinical-stage biotherapeutics
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Partnership and Licensing Revenue
TypeLicensing Royalties
Description

HiFiBiO generates revenue through upfront payments, milestone payments (clinical, regulatory, commercial), and royalties on net sales from partnered programs. Examples include the FibroGen partnership generating $25M upfront plus up to $1.1B in milestones across three programs, and a $35M option exercise payment for the CCR8 program.

hifibio.com
2Internal Pipeline Development and Commercialization
TypeSubscription Recurring
Description

Development and potential commercialization of proprietary immunotherapies targeting cancer and autoimmune diseases through the company's internal pipeline of clinical-stage programs.

hifibio.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

HiFiBiO Therapeutics is a clinical-stage biotech that develops transformative immunotherapies for cancer and autoimmune diseases using its proprietary Drug Intelligence Science (DIS®) platform, which combines single-cell technology with AI/ML analytics. The company advances an internal pipeline of monoclonal antibody candidates (e.g., Emunkitug, Nuvustotug, HFB200603, HFB200604) and monetizes select assets through out-licensing and co-development partnerships with pharmaceutical companies.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 8 clinical candidates discovered and advanced, including first-in-class and best-in-class programs
+4 more records
Product overview1 text field

HiFiBiO Therapeutics is a clinical-stage biotech with a platform-plus-pipeline architecture. The core is the Drug Intelligence Science (DIS®) platform, which combines proprietary single-cell technology with AI/ML analytics to drive immunotherapy discovery and development. DIS® is comprised of the CelliGo™ microfluidic antibody discovery system and AbSolution™ bioinformatics software. The company advances a sustainable pipeline of immunomodulatory antibodies targeting both immuno-oncology (IO) and immunology & inflammation (I&I) diseases. The IO pipeline includes three Phase I clinical programs: Emunkitug (TNFR2 agonist), Nuvustotug (OX40 agonist), and HFB200603 (BTLA antagonist). The I&I pipeline includes HFB200604 (BTLA agonist, IND cleared) and preclinical programs (HFB3024, HFB100204, HFB2025). The company maintains strategic partnerships including FibroGen (Galectin-9, CXCR5, CCR8 programs) and Novartis (clinical supply for tislelizumab combinations).

Product and service4 records
1DIS® Platform (Drug Intelligence Science)
CategoryDrug discovery platform
Description

Proprietary translational platform combining single-cell technology with AI/ML analytics used by HiFiBiO and its partners to identify novel targets, select antibody drug candidates, and define predictive biomarkers for patient stratification across immuno-oncology and immunology & inflammation (I&I) programs.

2CelliGo™
CategoryDrug discovery platform
Description

Microfluidic-based screening platform that enables rapid identification of antibody candidates by screening millions of species-agnostic B cells within hours, supporting antibody discovery from patient samples.

3AbSolution™
CategoryDrug discovery platform
Description

Bioinformatics and machine-learning software for analyzing single B cell sequencing data, guiding antibody binding prediction and affinity maturation within the DIS® platform workflow.

4Emunkitug (HFB200301)
Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership8 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-04-16
Description

Grant-funded collaboration with UMass Chan Medical School to research Long COVID and ME/CFS using HiFiBiO's DIS® platform for single-cell profiling of patient samples. Investigators include Dr. Liisa Selin and Dr. Anna Gil. The research focuses on immune repertoire profiling and identifying targets of B and T cell responses.

Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2023-12-11
Description

HiFiBiO joined the REMISSION consortium (Rapid Evaluation of Molecular & Immune Status for Stratified Immunotherapies in Oncology) under France 2030 Initiative, led by Institut Gustave Roussy. The company facilitates access to its three clinical-stage IO programs and applies DIS® for treatment optimization. This is a flagship collaboration involving academic and industry leaders.

Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2023-12-11
Description

The France 2030 Initiative funds the REMISSION consortium for personalized immunotherapies based on immune profiling rather than tumor histology. HiFiBiO is a key industry contributor to this national initiative.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-06-23
Description

Clinical supply agreement for evaluation of HFB200301 (TNFR2 agonist) in combination with tislelizumab in DIS®-selected advanced solid tumors. Novartis supplies tislelizumab; HiFiBiO maintains global R&D and commercial rights for HFB200301.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-11-18
Description

Clinical trial supply agreement with Novartis to evaluate HFB200603 (BTLA antagonist) in combination with tislelizumab (Novartis' anti-PD-1) in DIS®-selected advanced solid tumors. Novartis supplies tislelizumab while HiFiBiO maintains control of the HFB200603 program including global R&D and commercial rights.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-12-20
Description

FibroGen exercised its exclusive license option for HiFiBiO's anti-CCR8 monoclonal antibody program (HFB1011/HFB101110). HiFiBiO received a $35M option exercise payment plus potential milestones and royalties. FibroGen has sole right to develop all products worldwide.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-06-17
Description

FibroGen exclusively licensed HiFiBiO's Galectin-9 program and obtained exclusive options for CXCR5 and CCR8 programs. HiFiBiO received $25M upfront plus up to $1.1B in future milestones across all three programs plus royalties. The partnership represents significant validation of the DIS® approach.

8World-renowned Industry and Academic Researchers
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Open-innovation partnerships with industry leaders and academic researchers for collaborative research on disease biology, translational medicine, and immune profiling.

hifibio.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage biotech developing conditionally activated immunotherapies for cancer with a platform approach (PREDATOR), directly competing with HiFiBiO in next-generation IO biologics and seeking pharma partnerships to advance assets.

TypeDirect peer
Description

Clinical-stage antibody biotech with multiple IO programs (CTX-009, CTX-471, CTX-112) targeting similar immuno-oncology mechanisms, also pursuing a discovery platform-plus-pipeline model with partnership optionality.

TypeDirect peer
Description

Clinical-stage antibody biotech with a POWERbody and SAFEbody platform for conditionally activated antibodies in oncology, pursuing IO clinical assets with a similar platform-plus-pipeline approach as HiFiBiO.

TypeDirect peer
Description

Computational biology-driven biotech that uses AI/bioinformatics to discover novel IO targets and has its own clinical-stage antibody pipeline, sharing HiFiBiO's AI/ML-enabled biologic discovery orientation.

5Atreca
TypeDirect peer
Description

Clinical-stage antibody biotech using immune-repertoire sequencing and single-cell analysis to discover therapeutic antibodies directly from patient samples, a methodology that closely parallels HiFiBiO's DIS(R) single-cell approach.

TypeDirect peer
Description

Clinical-stage biotech developing immunomedicines for cancer and autoimmune disease with both an IO and I&I pipeline, structurally similar to HiFiBiO in its therapeutic-area breadth and antibody-centric approach.

TypeDirect peer
Description

Clinical-stage biotech developing rationally designed Immuno-STAT biologics for selective T cell modulation in cancer and autoimmune disease, working in overlapping IO/I&I indications with HiFiBiO.

TypeDirect peer
Description

Clinical-stage antibody biotech with a discovery platform producing multi-specific therapeutic proteins for cancer and rare diseases, sharing HiFiBiO's engineered-antibody discovery platform origin.

TypeDirect peer
Description

Clinical-stage biotech with antibody engineering platforms (Azymetric, ZymeLink) used to develop multispecific antibody therapeutics, comparable as a platform-enabled antibody developer with pharma partnerships.

TypeDirect peer
Description

China-based clinical-stage biotech developing a large bispecific/multispecific antibody pipeline for cancer and autoimmune diseases, comparable to HiFiBiO's Asia-Pacific antibody development operations and IO/I&I therapeutic focus.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability5 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries3 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors21 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

HiFiBiO Cambridge

Clinical-stage biotherapeuticshifibio.com

HiFiBiO Therapeutics is a private clinical-stage biotech using its proprietary DIS® single-cell and AI/ML platform to discover and develop immunotherapies for cancer and inflammatory diseases, monetising assets primarily through out-licensing and milestone-based partnerships with pharmaceutical companies.

What HiFiBiO Cambridge does

HiFiBiO Therapeutics is a private, clinical-stage biotherapeutics company developing immunotherapies for cancer and immunology & inflammation (I&I) diseases. The company is built around its proprietary Drug Intelligence Science (DIS®) platform, which combines single-cell screening technology — embodied in the CelliGo™ microfluidic system capable of screening millions of species-agnostic B cells within hours — with AI/ML-driven bioinformatics (AbSolution™) for antibody binding prediction, affinity maturation, target discovery, and predictive biomarker identification. HiFiBiO has internally discovered 8 clinical candidates, cleared 6 INDs, and completed 4 Phase I dose-escalation trials; its active clinical pipeline includes the TNFR2 agonist emunkitug (HFB200301), the BTLA antagonist HFB200603, the OX40 agonist nuvustotug (HFB301001), and the BTLA agonist HFB200604 in I&I.

The company operates laboratory and operational facilities across three continents — Cambridge (US headquarters), Paris (France, original single-cell platform site), Shanghai, Hangzhou, and Hong Kong (China) — and pursues an open-innovation business model centred on out-licensing and co-development. Revenue is generated via upfront payments, development and commercial milestones, and royalties from partners rather than direct product sales; the landmark FibroGen agreement (June 2021) delivered $25M upfront plus up to $1.1B in potential milestones across three programs, followed by a $35M option exercise payment for the CCR8 program in December 2021. Novartis has entered clinical-supply agreements for combination studies with tislelizumab, and HiFiBiO participates in the REMISSION consortium under the France 2030 Initiative. No products are commercially approved, and the company is funded by a $75M Series D (2021) alongside prior venture capital from IDG Capital, Mirae Asset Capital, HongShan, and Nest.Bio Ventures.

HiFiBiO Cambridge firmographics

Firmographics
Name
HiFiBiO Cambridge
Legal name
HiFiBiO Therapeutics, Inc.
Website
https://hifibio.com
Company type
Private
Founded year
2017
Operating status
Operating
Headcount range
51–100 employees
Short description
HiFiBiO Therapeutics is a private clinical-stage biotech using its proprietary DIS® single-cell and AI/ML platform to discover and develop immunotherapies for cancer and inflammatory diseases, monetising assets primarily through out-licensing and milestone-based partnerships with pharmaceutical companies.
Ownership category
akta.pro rank

HiFiBiO Cambridge industry classification

Industry
Product category
Clinical-stage biotherapeutics
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412)
SIC
Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • Immunotherapy drug discovery
  • Single cell antibody platform
  • Clinical stage biotherapeutics
  • Immuno oncology pipeline
  • Translational drug intelligence

Where HiFiBiO Cambridge is headquartered

Location

Headquarters

HQ city
Cambridge
HQ country
United States
HQ region
North America

Offices6 records

Markets served

HiFiBiO Cambridge business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Partnership and Licensing Revenue: HiFiBiO generates revenue through upfront payments, milestone payments (clinical, regulatory, commercial), and royalties on net sales from partnered programs. Examples include the FibroGen partnership generating $25M upfront plus up to $1.1B in milestones across three programs, and a $35M option exercise payment for the CCR8 program.
  2. Internal Pipeline Development and Commercialization: Development and potential commercialization of proprietary immunotherapies targeting cancer and autoimmune diseases through the company's internal pipeline of clinical-stage programs.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

HiFiBiO Cambridge product offering

Product offering

Core offering

HiFiBiO Therapeutics is a clinical-stage biotech that develops transformative immunotherapies for cancer and autoimmune diseases using its proprietary Drug Intelligence Science (DIS®) platform, which combines single-cell technology with AI/ML analytics. The company advances an internal pipeline of monoclonal antibody candidates (e.g., Emunkitug, Nuvustotug, HFB200603, HFB200604) and monetizes select assets through out-licensing and co-development partnerships with pharmaceutical companies.

Product overview

HiFiBiO Therapeutics is a clinical-stage biotech with a platform-plus-pipeline architecture. The core is the Drug Intelligence Science (DIS®) platform, which combines proprietary single-cell technology with AI/ML analytics to drive immunotherapy discovery and development. DIS® is comprised of the CelliGo™ microfluidic antibody discovery system and AbSolution™ bioinformatics software. The company advances a sustainable pipeline of immunomodulatory antibodies targeting both immuno-oncology (IO) and immunology & inflammation (I&I) diseases. The IO pipeline includes three Phase I clinical programs: Emunkitug (TNFR2 agonist), Nuvustotug (OX40 agonist), and HFB200603 (BTLA antagonist). The I&I pipeline includes HFB200604 (BTLA agonist, IND cleared) and preclinical programs (HFB3024, HFB100204, HFB2025). The company maintains strategic partnerships including FibroGen (Galectin-9, CXCR5, CCR8 programs) and Novartis (clinical supply for tislelizumab combinations).

Differentiator

Problem solved

Functional benefit

Products and services

  • DIS® Platform (Drug Intelligence Science) Proprietary translational platform combining single-cell technology with AI/ML analytics used by HiFiBiO and its partners to identify novel targets, select antibody drug candidates, and define predictive biomarkers for patient stratification across immuno-oncology and immunology & inflammation (I&I) programs.
  • CelliGo™ Microfluidic-based screening platform that enables rapid identification of antibody candidates by screening millions of species-agnostic B cells within hours, supporting antibody discovery from patient samples.
  • AbSolution™ Bioinformatics and machine-learning software for analyzing single B cell sequencing data, guiding antibody binding prediction and affinity maturation within the DIS® platform workflow.
  • Emunkitug (HFB200301)

Quantifiable outcome

  • 8 clinical candidates discovered and advanced, including first-in-class and best-in-class programs
  • +4 more outcomes

Companies that use HiFiBiO Cambridge

Customer profile

Segments2 records

Ideal customer profiles2 records

HiFiBiO Cambridge technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature4 records

HiFiBiO Cambridge partnerships and signals

Strategic signal

Partnerships

Eight partnerships are on record, tiered core, flagship and minor.

  • UMass Chan Medical SchoolcoreStrategic or Co-development Partner · 16 April 2024Grant-funded collaboration with UMass Chan Medical School to research Long COVID and ME/CFS using HiFiBiO's DIS® platform for single-cell profiling of patient samples. Investigators include Dr. Liisa Selin and Dr. Anna Gil. The research focuses on immune repertoire profiling and identifying targets of B and T cell responses.
  • Institut Gustave RoussyflagshipStrategic or Co-development Partner · 11 December 2023HiFiBiO joined the REMISSION consortium (Rapid Evaluation of Molecular & Immune Status for Stratified Immunotherapies in Oncology) under France 2030 Initiative, led by Institut Gustave Roussy. The company facilitates access to its three clinical-stage IO programs and applies DIS® for treatment optimization. This is a flagship collaboration involving academic and industry leaders.
  • France 2030 InitiativeflagshipStrategic or Co-development Partner · 11 December 2023The France 2030 Initiative funds the REMISSION consortium for personalized immunotherapies based on immune profiling rather than tumor histology. HiFiBiO is a key industry contributor to this national initiative.
  • NovartiscoreStrategic or Co-development Partner · 23 June 2023Clinical supply agreement for evaluation of HFB200301 (TNFR2 agonist) in combination with tislelizumab in DIS®-selected advanced solid tumors. Novartis supplies tislelizumab; HiFiBiO maintains global R&D and commercial rights for HFB200301.
  • NovartiscoreStrategic or Co-development Partner · 18 November 2022Clinical trial supply agreement with Novartis to evaluate HFB200603 (BTLA antagonist) in combination with tislelizumab (Novartis' anti-PD-1) in DIS®-selected advanced solid tumors. Novartis supplies tislelizumab while HiFiBiO maintains control of the HFB200603 program including global R&D and commercial rights.
  • FibroGencoreStrategic or Co-development Partner · 20 December 2021FibroGen exercised its exclusive license option for HiFiBiO's anti-CCR8 monoclonal antibody program (HFB1011/HFB101110). HiFiBiO received a $35M option exercise payment plus potential milestones and royalties. FibroGen has sole right to develop all products worldwide.
  • FibroGencoreStrategic or Co-development Partner · 17 June 2021FibroGen exclusively licensed HiFiBiO's Galectin-9 program and obtained exclusive options for CXCR5 and CCR8 programs. HiFiBiO received $25M upfront plus up to $1.1B in future milestones across all three programs plus royalties. The partnership represents significant validation of the DIS® approach.
  • World-renowned Industry and Academic ResearchersminorStrategic or Co-development PartnerOpen-innovation partnerships with industry leaders and academic researchers for collaborative research on disease biology, translational medicine, and immune profiling.

Scale indicators6 records

Recent moves6 records

Expansion highlights5 records

HiFiBiO Cambridge competitors and assessment

Company assessment

Direct peers

  • Werewolf Therapeutics: Clinical-stage biotech developing conditionally activated immunotherapies for cancer with a platform approach (PREDATOR), directly competing with HiFiBiO in next-generation IO biologics and seeking pharma partnerships to advance assets.
  • Compass Therapeutics: Clinical-stage antibody biotech with multiple IO programs (CTX-009, CTX-471, CTX-112) targeting similar immuno-oncology mechanisms, also pursuing a discovery platform-plus-pipeline model with partnership optionality.
  • Adagene: Clinical-stage antibody biotech with a POWERbody and SAFEbody platform for conditionally activated antibodies in oncology, pursuing IO clinical assets with a similar platform-plus-pipeline approach as HiFiBiO.
  • Compugen: Computational biology-driven biotech that uses AI/bioinformatics to discover novel IO targets and has its own clinical-stage antibody pipeline, sharing HiFiBiO's AI/ML-enabled biologic discovery orientation.
  • Atreca: Clinical-stage antibody biotech using immune-repertoire sequencing and single-cell analysis to discover therapeutic antibodies directly from patient samples, a methodology that closely parallels HiFiBiO's DIS(R) single-cell approach.
  • NextCure: Clinical-stage biotech developing immunomedicines for cancer and autoimmune disease with both an IO and I&I pipeline, structurally similar to HiFiBiO in its therapeutic-area breadth and antibody-centric approach.
  • Cue Biopharma: Clinical-stage biotech developing rationally designed Immuno-STAT biologics for selective T cell modulation in cancer and autoimmune disease, working in overlapping IO/I&I indications with HiFiBiO.
  • Inhibrx Biosciences: Clinical-stage antibody biotech with a discovery platform producing multi-specific therapeutic proteins for cancer and rare diseases, sharing HiFiBiO's engineered-antibody discovery platform origin.
  • Zymeworks: Clinical-stage biotech with antibody engineering platforms (Azymetric, ZymeLink) used to develop multispecific antibody therapeutics, comparable as a platform-enabled antibody developer with pharma partnerships.
  • Akeso: China-based clinical-stage biotech developing a large bispecific/multispecific antibody pipeline for cancer and autoimmune diseases, comparable to HiFiBiO's Asia-Pacific antibody development operations and IO/I&I therapeutic focus.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

HiFiBiO Cambridge social profiles

Digital presence

HiFiBiO Cambridge financial estimates

Financial estimate

Revenue estimate

Valuation estimate

HiFiBiO Cambridge leadership team

Management profile

Number of profiles

Profiles8 records

HiFiBiO Cambridge subsidiaries and ownership

Company hierarchy

Subsidiaries3 records

HiFiBiO Cambridge funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors21 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

HiFiBiO Cambridge M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about HiFiBiO Cambridge

What does HiFiBiO Cambridge do?

HiFiBiO Therapeutics is a clinical-stage biotech that develops transformative immunotherapies for cancer and autoimmune diseases using its proprietary Drug Intelligence Science (DIS®) platform, which combines single-cell technology with AI/ML analytics. The company advances an internal pipeline of monoclonal antibody candidates (e.g., Emunkitug, Nuvustotug, HFB200603, HFB200604) and monetizes select assets through out-licensing and co-development partnerships with pharmaceutical companies.

Is HiFiBiO Cambridge a public or private company?

HiFiBiO Cambridge is a private company. It is classified as venture growth investor backed and is currently operating.

When was HiFiBiO Cambridge founded?

HiFiBiO Cambridge was founded in 2017. It employs 51 to 100 people.

Where is HiFiBiO Cambridge based?

HiFiBiO Cambridge is headquartered in Cambridge, United States, in the North America region.

How does HiFiBiO Cambridge make money?

Two revenue lines are on record. Partnership and Licensing Revenue is the primary driver. The others are internal Pipeline Development and Commercialization.

Who are HiFiBiO Cambridge's main competitors?

Direct peers on record are Werewolf Therapeutics, Compass Therapeutics, Adagene, Compugen, Atreca, NextCure, Cue Biopharma, Inhibrx Biosciences, Zymeworks and Akeso.

Does HiFiBiO Cambridge have an API?

No public API is recorded for HiFiBiO Cambridge.

What industry is HiFiBiO Cambridge in?

HiFiBiO Cambridge's product category is Clinical-stage biotherapeutics. Its primary akta.pro industry code is HLAAAIAB, Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering), with a secondary code of HLAAAIAE, AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales